While Perspective Therapeutics Inc has underperformed by -6.39%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CATX fell by -35.74%, with highs and lows ranging from $5.39 to $1.60, whereas the simple moving average fell by -32.09% in the last 200 days.
On November 24, 2025, Truist started tracking Perspective Therapeutics Inc (AMEX: CATX) recommending Buy. A report published by BTIG Research on October 10, 2025, Initiated its previous ‘Buy’ rating for CATX. H.C. Wainwright also rated CATX shares as ‘Buy’, setting a target price of $10 on the company’s shares in an initiating report dated March 13, 2025. Scotiabank Initiated an Sector Outperform rating on March 07, 2025, and assigned a price target of $15. BofA Securities November 25, 2024d its ‘Buy’ rating to ‘Neutral’ for CATX, as published in its report on November 25, 2024. UBS’s report from October 24, 2024 suggests a price prediction of $20 for CATX shares, giving the stock a ‘Buy’ rating. Wedbush also rated the stock as ‘Outperform’.
Analysis of Perspective Therapeutics Inc (CATX)
Further, the quarter-over-quarter decrease in sales is -43.36%, showing a negative trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Perspective Therapeutics Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -37.24% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.66, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and CATX is recording an average volume of 1.46M. On a monthly basis, the volatility of the stock is set at 8.87%, whereas on a weekly basis, it is put at 7.53%, with a loss of -5.53% over the past seven days. Furthermore, long-term investors anticipate a median target price of $12.31, showing growth from the present price of $2.05, which can serve as yet another indication of whether CATX is worth investing in or should be passed over.
How Do You Analyze Perspective Therapeutics Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 17.09%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 63.29% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
